Biopharma’s next “win” won’t come from science alone—it’ll come from timing, tender strategy, and a ruthless understanding of how markets behave after patent loss.
If you’re selling to European healthcare systems—whether you’re a commercial vendor, a t…
Pharma’s “new drug” playbook isn’t always new chemistry—it’s new math.
For years, the industry has sold the story that innovation is synonymous with novelty: new molecules, new mechanisms, new patents. But a growing body of evidence suggests a differ…
Biopharma is entering a new kind of “cliff”—not the one investors talk about in earnings calls, but the one that shows up in procurement meetings.
When a blockbuster approaches loss of exclusivity, the market doesn’t just get cheaper. It gets noisier. …
One-shot strategy: how to pick the right drug patent for maximum extension value
Most pharma teams don’t lose because they miss the science. They lose because they miss the clock.
Drug patent term extension (and related exclusivity extensions) can add …
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drugmakers don’t lose to competitors—they lose to the clock.
In patent litigation, timing is everything. But in the quieter, earlier phase—design-around planning—the real risk isn’t just whether a competitor can be sued. It’s whether your team can pr…
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion problem—and it’s not just about patents. It’s about time.
For years, the industry has treated patent term as a technicality: file early, prosecute smart, and move on. But the real value of exclusivity isn’t theoretical—it’s op…
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose deals because they miss a clinical endpoint.
They lose deals because they miss the map.
Eurasia—where regulatory pathways, patent enforcement, and market access rules don’t always behave like they do in the US or EU—can tur…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Pharma patent strategy is often treated like a filing exercise. It shouldn’t be.
In the pharmaceutical business, patents aren’t just legal instruments—they’re balance-sheet assets, pipeline accelerators, and negotiation leverage. Yet too many companies…
Get new actionable insights and updates from BiotechBlog
